Mipharm S.p.A

On September 26, 2024, Doppel Farmaceutici and Mipharm completed a merger to form the new CDMO group Domixtar Pharmaceutical (DMX Pharma). Building on a consolidated tradition in the sector, the new group offers a broad portfolio of technologies and products across a wide range of therapeutic applications, including anti-tumoral, corticosteroid, anti-inflammatory, cardiovascular, metabolic and gastrointestinal treatments, treatments for severe headaches, and homeopathic products prepared by Alfa Omega, a subsidiary of Mipharm.